Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC
Phase of Trial: Phase I/II
Latest Information Update: 23 Nov 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Oct 2019 Status changed from suspended to recruiting.
- 02 Oct 2019 Status changed from recruiting to suspended.
- 20 Nov 2018 Status changed from not yet recruiting to recruiting.